| Oct 31 |
Halozyme Therapeutics: Q3 Earnings Snapshot
|
| Oct 31 |
Halozyme Therapeutics Non-GAAP EPS of $1.27 beats by $0.27, revenue of $290.1M beats by $37.93M
|
| Oct 31 |
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
|
| Oct 30 |
Halozyme Therapeutics Q3 2024 Earnings Preview
|
| Oct 30 |
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
|
| Oct 25 |
Unveiling 12 Analyst Insights On Halozyme Therapeutics
|
| Oct 24 |
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
|
| Oct 23 |
Halozyme to Report Third Quarter 2024 Financial and Operating Results
|
| Oct 22 |
Halozyme Therapeutics: Behind The Pullback
|
| Oct 14 |
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
|
